IL6 and colitis: In this sense, pioglitazone, a nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, has been shown to inhibit human and murine Th17 differentiation by reducing TGFβ/IL-6-induced expression of RORγt [125], and indeed, it has proven to be favourable in mouse DSS-induced colitis [126].